Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2026 Financials
Jaguar Health (NASDAQ:JAGX) reported Q2 2026 financials, showing a 59% revenue decline to $1.2M and a net loss of $12.7M. The company is focused on developing crofelemer for rare intestinal diseases, with a planned NDA submission in Q2 2027. Non-GAAP recurring EBITDA loss was $8.4M, a 6% increase from the prior year. Jaguar will host an investor webcast on August 19, 2026, to discuss results and updates.
How this was made
The 30-second read
Why it matters
The earnings release underscores a steep revenue decline and widening losses, suggesting near‑term pressure but long‑term pipeline value.
Market read
The report provides fresh financial data for a small‑cap biotech, relevant for investors tracking rare‑disease drug developers.
What to watch
Potential revenue from upcoming crofelemer indications and partnership opportunities not reflected in current loss.
Background
Jaguar Health focuses on plant‑derived therapies for rare gastrointestinal disorders, with recent data on crofelemer in pediatric intestinal failure.
Ticker impact
Jaguar Health reported Q2 2026 results with a 59% revenue decline and a net loss of $12.69M, marking the first public disclosure of these numbers.
Potential downside of 5‑10% over the next few days.
Revenue and loss figures were worse than prior year, and guidance for an NDA filing in Q2 2027 adds uncertainty.
Market effects
Highlights challenges in the niche biotech/rare disease sector, possibly affecting peer valuations.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond specialty pharma niche.
Counterpoint
If the NDA filing proceeds on schedule, the long‑term upside could outweigh short‑term earnings weakness.
Key entities
- CompanyJaguar Health, Inc.
Developer of crofelemer‑based therapies, ticker JAGX.
- SubsidiaryNapo Pharmaceuticals
Jaguar's family company responsible for crofelemer production.
